Effect of zinc replacement on lipids and lipoproteins in type 2-diabetic patients

Biomedicine and Pharmacotherapy

Volumn 60, Issue 4, 2006, Pages 161-168

  Partida Hernandez G ^a,b,c   Arreola, F ^c   Fenton, B ^a   Cabeza, M ^d   Roman Ramos R ^e   Revilla Monsalve, M C ^f  

^a Faculty of Medical and Biological Sciences   (Mexico)

^b UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^c Diabetes Education and Medical Attention Center   (Mexico)

^d DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^e DEPARTAMENTO DE QUÍMICA   (Mexico)

^f INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Diabetes mellitus; Lipids; Zinc replacement

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ZINC SULFATE; CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; HYPOGLYCEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; MEXICO; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; LIPID METABOLISM; METABOLISM; MIDDLE AGED;

ADULT; AGED; CHOLESTEROL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HUMANS; LIPID METABOLISM; MALE; MEXICO; MIDDLE AGED; TRIGLYCERIDES; ZINC SULFATE;

EID: 33745056496     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.02.004     Document Type: Article

References (67)

1. Stamler J., Vaccaro O., Neaton J.D., and Wenworth D. Diabetes, other risk factors and 12 years cardiovascular mortality for men screened in the multiple risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
2. Estadísticas del Sector Salud y Seguridad Social. Instituto Nacional de Estadística, Geografía e Informática. México. Edición 2003. Cuaderno Núm. 20.
3. Haffner S.M. Impaired glucose tolerance, insulin resistance and cardiovascular disease. Diabet. Med. 14 (1997) S14-S18
4. Islas S., and Revilla M.C. Diabetes y dislipidemias. En: Islas S, Revilla-Monsalve MC editores. Diabetes mellitus. Tercera edición (2005), McGraw-Hill Interamericana, México 484-499
5. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care Health Module 2003;26:S5-S20.
6. The Diabetes Control and Complications Trial Research Group. Intensive treatment of the diabetes and complications in the DMID. N. Engl. J. Med. 329 (1993) 977-986
7. La diabetes mellitus tipo 2: guía diagnóstico terapéutica. Rev. Med. IMSS 35 5 (1997) 353-368
8. American Diabetes Association. Therapy for diabetes mellitus and related disorders. Third edition (1998), Clinical Education Series
9. Alpízar Salazar M. Enfermedad cardiovascular y diabetes. En: Guía para el manejo integral del paciente diabético.Serie Fascicular. Editorial El Manual Moderno, S.A. de C.V.; 2001. p. 107.
10. Aguilar S.A.C., Gómez P.J.F., Lerman G.I., Vázquez C.H.C., Pérez M.O., and Posadas R.C. Diagnóstico y tratamiento de las dislipidemias: posición de la Sociedad mexicana de nutrición y endocrinologia. Rev. End. Nutr. 12 1 (2004) 7-41
11. Wood R.J. Assessment of marginal zinc status in humans. J. Nutr. 130 (2000) 1350S-1354S
12. King J.C., Shames D.M., and Woodhouse L.R. Zinc homeostasis in humans. J. Nutr. 130 (2000) 1360S-1366S
13. Black R.E. Zinc deficiency, infections disease and mortality in the developing world. J. Nutr. 133 (2003) 1485S-1489S
14. Arreola F., Paniagua R., Díaz-Bensussen S., Urquieta B., López-Montaño E., Partida- Hernández G., et al. Bone mineral content, 25-hydroxycalciferol and zinc serum levels in insulin dependent (type 1) diabetic patients. Arch. Invest. Med. (Mex.) 21 (1990) 195-199
15. Paniagua R., Arreola F., Herrera J., Pérez A., Díaz S., Mondragón L., et al. Impaired androgen synthesis in uremic patients. Evidence of enzymatic blockage and a possible role of zinc. Rev. Invest. Clin. 33 (1981) 14-21
16. Bermúdez J.A., Paniagua R., Arreola F., Herrera J., Pérez A., Díaz S., et al. Endocrine profile, in patients with chronic renal failure under zinc replacement. Arch. Androl. 9 (1982) 167-169
17. Baumgartner T.G. Trace elements in clinical nutrition. NCP 8 6 (1993) 251-263
18. Endin S.O., Dodson G.G., Cutfield J.M., and Cutfield S.M. Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell. Diabetologia 19 3 (1980) 174-182
19. Ward N.I. Assessment of zinc status and oral supplementation in anorexia nervosa. J. Nutr. Med. 1 (1990) 171-177
20. Chausmer A.B. Zinc, insulin and diabetes. J. Am. Coll. Nutr. 17 2 (1998) 109-115
21. Mooradin D.A., Failla M., Hoogwer B., Maryniuk M., and Wylie-Rosett J. Selected vitamins and minerals in diabetes. Diabetes Care 17 5 (1994) 464-479
22. O'Connell B.S. Selected vitamins and minerals in the management of diabetes. Diabetes Spectrum 14 3 (2001) 133-148
23. Arreola F., Flores S., Junco E., Mondragón L., Díaz-Bensussen S., Pérez-Pastén E., et al. Effect of zinc on somatomedin-C concentration in insulin-dependent diabetic children. Diabetes 38 Suppl 2 (1989) 124 (-A)
24. Arreola F., Licea M., Mondragón L., Partida-Hernández G., Díaz-Bensussen S., Pérez- Pastén E., et al. Thyroid function in insulin-dependent diabetic children under zinc replacement. Diabetes 39 Suppl 1 (1990) 295 (-A)
25. Arreola F., Herrera R., Junco E., Díaz-Bensussen S., Pérez-Pastén E., and Partida-Hernández G. Effect of zinc replacement on gonadal function type 1-diabetes mellitus. Diabetes 40 Suppl 1 (1991) 490 (-A)
26. Arreola F., Flores S., Junco E., Mondragón L., Díaz S., Mendoza F., et al. Efecto del zinc sobre somatomedina-C y velocidad de crecimiento en niños con diabetes mellitus tipo 1. Bol. Med. Hosp. Infant. Mex. 49 10 (1992) 709
27. Faure P., Benhamou P.Y., Perard A., Halimi S., and Roussel A.M. Lipidperoxidation in insulin-dependent diabetic patients with early retina degenerative lesions: effects of an oral zinc supplementation. Eur. J. Clin. Nutr. 49 (1995) 282-288
28. Urquieta B., Paniagua R., Pérez E., Exaire E., Arreola F., Junco E., et al. Mejoría en las concentraciones séricas de hormonas tiroideas en insuficientes renales crónicos, después de la administración oral de zinc. Arch. Invest. Med. (Mex.) 13 Suppl 1 (1982) 10
29. Arreola F., Paniagua R., Pérez A., Díaz S., Junco E., Villalpando S., et al. Effect of zinc treatment on serum thyroid hormones in uremic patients under peritoneal dialysis. Horm. Metab. Res. 25 10 (1993) 539-542
30. Sustrova M., and Strabak V. Thyroid function and plasma immunoglobulins in subjects with Down syndrome (DS) during ontogenesis and zinc therapy. J. Endocrinol. Invest. 17 (1994) 585-590
31. Relea P., Revilla M., and Ripoll E. Zinc, biochemical markers of nutrition, and type-I osteoporosis. Age Ageing 24 (1995) 303-307
32. Gómez-García A., and Magaña G.P. Papel del cromo y del cinc en el metabolismo de la insulina. Rev. Med. IMSS 42 4 (2004) 347-352
33. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 284 23 (2000) 3043-3045
34. Sandstead H.H. Requirements and toxicity of essential trace elements illustrated by zinc and cooper. Am. J. Clin. Nutr. 2 Suppl 3 (1995) 62-65 (GI)
35. Taylor A. Detection and monitoring of disorders of essential trace elements. Ann. Clin. Biochem. 33 (1996) 486-510
36. NOM-174-SSA1-1998. Norma Oficial Mexicana. Para el Manejo integral de la obesidad. Diario Oficial de la Federación 12 Abril 2000.
37. American Diabetes Association. Clinical practice recommendations standards of medical care in diabetes. Diabetes Care 28 (2005) S4-S36
38. Asociación Latinoamericana de Diabetes. Control clínico y metabólico de la DM2. Rev. Assoc. Latinoam. Diab. 2000; Suppl 1, ed. Extraordinaria.
39. Butrimovitz G.P., and Pudri W.C. The determination of zinc in blood plasma by atomic absorption spectrometry. Anal. Chim. Acta 94 (1977) 63
40. Sebia H.Y.D.R.A.S.I.S. International handbook (1998), International Sebia Inc., France
41. International Lipid Information Bureau. The ILIB lipid handbook for clinical practice (1998), Waverly Hispanica, S.A, Argentina 26-50 (137-141)
42. Green B.S., Salkind J.N., and Akey M.T. Using SPSS for windows. Analyzing and understanding data. Second edition (2000), Prentice Hall, New Jersey 143-148 (234-242)
43. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
44. Bakker J.A. Detection of microalbuminuria. Diabetes Care 22 2 (1999) 307-313
45. Defronzo R.A. Diabetes nephropathy. Etiologic and therapeutic considerations. Diabetes Rev. 3 (1995) 510-564
46. Gross L.J., De Azevedo J.M., and Silveiro P.S. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 38 1 (2005) 176-188
47. American Diabetes Association, American College of Physicians, and American Academy of Ophthalmology. Screening guidelines for diabetic retinopathy, clinical guidelines. Ophthalmology 99 (1992) 1626-1628
48. Vázquez-Vega B., Meza M.L.M., and Islas S. Nefropatía diabética. In: Islas S., and Revilla- Monsalve M.C. (Eds). Diabetes mellitus. Tercera edición (2005), McGraw-Hill Interamericana, México 330-347
49. Estadística del Sector Salud y Seguridad Social. Instituto Nacional de Estadística, Geografía e Informática. Cuaderno 17. México; 2001. pp. 60-63.
50. Diabetes Prevention Program Research Group, Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2-diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 6 (2002) 393-403
51. Finnish Diabetes Prevention Study Group, Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2-diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344 18 (2001) 1343-1350
52. Bastarrachea A.R., Laviada-Molina H., and Vázquez-Chávez C. Análisis crítico de los nuevos criterios que sustentan el diagnóstico de prediabetes. Rev. End. Nutr. 12 2 (2004) 90-96
53. Amador R.O.L., and Legorreta-Soberanis J. Distribución de grasa corporal en diabéticos tipo 2, como factor de riesgo cardiovascular. Rev. Med. IMSS 43 3 (2005) 199-204
54. Howard B.V., Davis M.P., and Pettitt D.J. Plasma and lipoprotein cholesterol and triglyceride concentrations in the Pima Indians. Distributions differing from chose of Caucasians. Circulation 68 (1983) 714-724
55. Klaus-Helge I., and Lothar R. Zinc-altered immune function. J. Nutr. 133 (2003) 1452S-1456S
56. Abdel-Mageed A.B., and Oehme F.W. A review of the biochemical roles, toxicity and interactions of zinc, copper and iron. I. Zinc. Vet. Hum. Toxicol. (1990) 32-39
57. Arreola F., Paniagua R., Herrera J., Díaz S., Mondragón L., Bermúdez J.A., et al. Low plasma zinc and androgen in insulin-dependent diabetes mellitus. Arch. Androl. 16 (1986) 151-154
58. Seidell J.C., Ciugolini M., and Deslypere J.P. Body fat distribution in relation to serum lipids and blood pressure in 38-years-old European men. The European fat. Distribution Study. Atherosclerosis 86 (1991) 251-260
59. Howard V.B. Obesidad y metabolismo de las lipoproteínas: relación con la enfermedad cardiovascular. In: Fletcher F.G., Grundy M.S., and Hayman L. (Eds). Obesidad: impacto en la enfermedad cardiovascular. Segunda edición (2002), Futura Publishing Company, Inc, España 87-97
60. American Medical Association. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 157 (1997) 2423
61. Wood P.D., Stefanick M.L., and Williams P.T. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N. Engl. J. Med. 325 (1991) 461-466
62. Baron B.R. Anomalías de los lípidos. In: Tierney Jr. M.L., McPhee J.S., and Papadakis A.M. (Eds). Diagnóstico Clínico y Tratamiento. 37a edición (2002), Editorial El Manual Moderno SA de CV, Mexico city 1217-1230
63. a Sesión Científica Anual del American College of Cardiology Foundation . Atlanta, GA. Edit. por Intersistemas, S.A. de C.V. México.2003.
64. Massie M.B. Hipertensión Sistémica. In: Tierney Jr. M.L., McPhee J.S., and Papadakis M. (Eds). Diagnóstico Clínico y Tratamiento. 37a edición (2002), Editorial El Manual Moderno SA de CV, Mexico city 447-472
65. Grimm Jr. R.H., Flack J.M., Grandits G.A., and For the treatment of mild hypertension study (TOMHS) Research Group. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 275 (1996) 1549-1556
66. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 5 (2003) 1210-1214
67. Hambidge M., Cousins J.R., and Costello B.R. Introduction. In: Zinc and health current status and future directions. J. Nutr. 130 (2000) 1341S-1343S